{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T19:00:01Z","timestamp":1774638001046,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association Imagine for Margo"},{"DOI":"10.13039\/501100004097","name":"Fondation ARC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012094","name":"F\u00e9d\u00e9ration Enfants Cancers Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018001","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de lutte contre les Cancers et les leuc\u00e9mies de l'Enfant et de l'Adolescent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014206","name":"Dell","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014206","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cyclacel"},{"DOI":"10.13039\/501100008545","name":"Asociaci\u00f3n Pablo Ugarte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016916","name":"Royal Marsden Cancer Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016916","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Parrainage m\u00e9decin-chercheur of Gustave Roussy"},{"DOI":"10.13039\/501100007241","name":"Universit\u00e9 Paris-Saclay","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11523-026-01208-1","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:41:14Z","timestamp":1773661274000},"page":"199-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I\/II Study of the CDK2\/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcS\u00e9-ESMART Trial"],"prefix":"10.1007","volume":"21","clinical-trial-number":[{"clinical-trial-number":"nct2813135","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alba","family":"Rubio-San-Sim\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynley V.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Karamouza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Abbou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souad","family":"Nebchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estelle","family":"Thebaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Brisset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Ducassou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gw\u00e9na\u00ebl","family":"Le Teuff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-3643","authenticated-orcid":false,"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"12","key":"1208_CR1","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(22)00637-4","volume":"23","author":"L Botta","year":"2022","unstructured":"Botta L, Gatta G, Capocaccia R, Stiller C, Ca\u00f1ete A, Dal Maso L, et al. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study. Lancet Oncol. 2022;23(12):1525\u201336.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1208_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Moss\u00e9","year":"2013","unstructured":"Moss\u00e9 YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472\u201380.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1208_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"1208_CR4","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","volume":"26","author":"M Wong","year":"2020","unstructured":"Wong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A, et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020;26(11):1742\u201353.","journal-title":"Nat Med"},{"issue":"5","key":"1208_CR5","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1158\/2159-8290.CD-21-1136","volume":"12","author":"P Berlanga","year":"2022","unstructured":"Berlanga P, Pierron G, Lacroix L, Chicard M, Adam de Beaumais T, Marchais A, et al. The European MAPPYACTS Trial: precision medicine program in pediatric and adolescent patients with recurrent malignancies. Cancer Discov. 2022;12(5):1266\u201381.","journal-title":"Cancer Discov"},{"issue":"11","key":"1208_CR6","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/2159-8290.CD-21-0094","volume":"11","author":"CM van Tilburg","year":"2021","unstructured":"van Tilburg CM, Pfaff E, Pajtler KW, Langenberg KPS, Fiesel P, Jones BC, et al. The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets. Cancer Discov. 2021;11(11):2764\u201379.","journal-title":"Cancer Discov"},{"key":"1208_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ejca.2022.09.001","volume":"175","author":"KPS Langenberg","year":"2022","unstructured":"Langenberg KPS, Meister MT, Bakhuizen JJ, Boer JM, van Eijkelenburg NKA, Hulleman E, et al. Implementation of paediatric precision oncology into clinical practice: the individualized therapies for children with cancer program \u2018iTHER.\u2019 Eur J Cancer. 2022;175:311\u201325.","journal-title":"Eur J Cancer"},{"key":"1208_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114201","volume":"208","author":"B Geoerger","year":"2024","unstructured":"Geoerger B, Bautista F, Andr\u00e9 N, Berlanga P, Gatz SA, Marshall LV, et al. Precision cancer medicine platform trials: Concepts and design of AcS\u00e9-ESMART. Eur J Cancer. 2024;208:114201.","journal-title":"Eur J Cancer"},{"issue":"12","key":"1208_CR9","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1038\/s41591-023-02580-5","volume":"29","author":"B Geoerger","year":"2023","unstructured":"Geoerger B, Paoletti X, Bautista F, Gatz SA, Marshall LV, Andr\u00e9 N, et al. AcS\u00e9-ESMART, a European precision cancer medicine proof-of-concept platform trial. Nat Med. 2023;29(12):2985\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"1208_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10(1):11.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1208_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"key":"1208_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.apcsb.2023.02.001","volume":"135","author":"A Gupta","year":"2023","unstructured":"Gupta A, Dagar G, Chauhan R, Sadida HQ, Almarzooqi SK, Hashem S, et al. Cyclin-dependent kinases in cancer: role, regulation, and therapeutic targeting. Adv Protein Chem Struct Biol. 2023;135:21\u201355.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"1208_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678559","volume":"11","author":"AT Anshabo","year":"2021","unstructured":"Anshabo AT, Milne R, Wang S, Albrecht H. CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Front Oncol. 2021;11:678559.","journal-title":"Front Oncol"},{"key":"1208_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2022.04.028","volume":"170","author":"NA Schubert","year":"2022","unstructured":"Schubert NA, Chen CY, Rodr\u00edguez A, Koster J, Dowless M, Pfister SM, et al. Target actionability review to evaluate CDK4\/6 as a therapeutic target in paediatric solid and brain tumours. Eur J Cancer. 2022;170:196\u2013208.","journal-title":"Eur J Cancer"},{"issue":"8027","key":"1208_CR15","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","volume":"632","author":"P P\u00f6l\u00f6nen","year":"2024","unstructured":"P\u00f6l\u00f6nen P, Di Giacomo D, Seffernick AE, Elsayed A, Kimura S, Benini F, et al. The genomic basis of childhood T-lineage acute lymphoblastic leukaemia. Nature. 2024;632(8027):1082\u201391.","journal-title":"Nature"},{"issue":"1","key":"1208_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/cncr.29706","volume":"122","author":"KR Bosse","year":"2016","unstructured":"Bosse KR, Maris JM. Advances in the translational genomics of neuroblastoma: from improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer. 2016;122(1):20\u201333.","journal-title":"Cancer"},{"key":"1208_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00211","volume":"6","author":"JY Hsu","year":"2022","unstructured":"Hsu JY, Seligson ND, Hays JL, Miles WO, Chen JL. Clinical utility of CDK4\/6 inhibitors in sarcoma: successes and future challenges. JCO Precis Oncol. 2022;6:e2100211.","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"1208_CR18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126\u201339.","journal-title":"Cell"},{"issue":"5","key":"1208_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrm3567","volume":"14","author":"FA Dick","year":"2013","unstructured":"Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol. 2013;14(5):297\u2013306.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"1208_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234103","volume":"15","author":"S Frame","year":"2020","unstructured":"Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, et al. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS ONE. 2020;15(7):e0234103.","journal-title":"PLoS ONE"},{"key":"1208_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","volume":"173","author":"SR Whittaker","year":"2017","unstructured":"Whittaker SR, Mallinger A, Workman P, Clarke PA. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. 2017;173:83\u2013105.","journal-title":"Pharmacol Ther"},{"issue":"15","key":"1208_CR22","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","volume":"140","author":"S Lim","year":"2013","unstructured":"Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140(15):3079\u201393.","journal-title":"Development"},{"issue":"1","key":"1208_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00496-y","volume":"7","author":"W Chantkran","year":"2021","unstructured":"Chantkran W, Hsieh YC, Zheleva D, Frame S, Wheadon H, Copland M. Interrogation of novel CDK2\/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML. Cell Death Discov. 2021;7(1):137.","journal-title":"Cell Death Discov"},{"issue":"11","key":"1208_CR24","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1172\/JCI134132","volume":"130","author":"E Poon","year":"2020","unstructured":"Poon E, Liang T, Jamin Y, Walz S, Kwok C, Hakkert A, et al. Orally bioavailable CDK9\/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. J Clin Invest. 2020;130(11):5875\u201392.","journal-title":"J Clin Invest"},{"key":"1208_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ebiom.2018.12.022","volume":"39","author":"H Ma","year":"2019","unstructured":"Ma H, Seebacher NA, Hornicek FJ, Duan Z. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. EBioMedicine. 2019;39:182\u201393.","journal-title":"EBioMedicine"},{"issue":"13_Supplement","key":"1208_CR26","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-CT037","volume":"78","author":"KT Do","year":"2018","unstructured":"Do KT, Chau N, Wolanski A, Beardslee B, Hassinger F, Bhushan K, et al. Abstract CT037: Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). Cancer Res. 2018;78(13_Supplement):CT037.","journal-title":"Cancer Res"},{"issue":"16_suppl","key":"1208_CR27","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1200\/JCO.2024.42.16_suppl.3125","volume":"42","author":"MA Villalona-Calero","year":"2024","unstructured":"Villalona-Calero MA, Oh DY, Garralda E, Vieito M, Huang J, Piha-Paul SA. A Phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2\/9 inhibitor, in patients with advanced solid tumors and lymphoma. J Clin Oncol. 2024;42(16_suppl):3125.","journal-title":"J Clin Oncol"},{"key":"1208_CR28","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S0959-8049(20)31086-8","volume":"138","author":"KT Do","year":"2020","unstructured":"Do KT, Frej K, Bhushan K, Pruitt-Thompson S, Zheleva D, Blake D, et al. Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). Eur J Cancer. 2020;138:S7.","journal-title":"Eur J Cancer"},{"key":"1208_CR29","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05168904?intr=fadraciclib&rank=1 [Internet]. 2025. A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)."},{"key":"1208_CR30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ejca.2017.09.015","volume":"86","author":"F Bautista","year":"2017","unstructured":"Bautista F, Moreno L, Marshall L, Pearson ADJ, Geoerger B, Paoletti X. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: an analysis from the Innovative Therapies for Children with Cancer Consortium. Eur J Cancer. 2017;86:275\u201384.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1208_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1208_CR32","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963\u201372.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1208_CR33","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","volume":"35","author":"JR Park","year":"2017","unstructured":"Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, et al. Revisions to the International neuroblastoma response criteria: a consensus statement from the National Cancer Institute clinical trials planning meeting. J Clin Oncol. 2017;35(22):2580\u20137.","journal-title":"J Clin Oncol"},{"key":"1208_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113525","volume":"198","author":"N Andr\u00e9","year":"2024","unstructured":"Andr\u00e9 N, Le DMC, L\u00e9guillette C, Probst A, Willems L, Travers R, et al. METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing\/refractory solid tumors. Eur J Cancer. 2024;198:113525.","journal-title":"Eur J Cancer"},{"key":"1208_CR35","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.2147\/DDDT.S305792","volume":"15","author":"C Shi","year":"2021","unstructured":"Shi C, Wang X, Diao C, Zhu H, Yuan Q, Liu J, et al. Toxicities and associated factors in patients receiving Temozolomide-containing regimens: a 12-year analysis of hospital data. Drug Des Devel Ther. 2021;15:2151\u20139.","journal-title":"Drug Des Devel Ther."},{"issue":"12_Supplement","key":"1208_CR36","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-19-C002","volume":"18","author":"T Cash","year":"2019","unstructured":"Cash T, Aguilera D, Macy ME, Hoffman L, Dorris K, McCracken C, et al. Abstract C002: Phase 1 study of abemaciclib in children with recurrent and refractory solid tumors including malignant brain tumors. Mol Cancer Ther. 2019;18(12_Supplement):C002.","journal-title":"Mol Cancer Ther"},{"issue":"16_suppl","key":"1208_CR37","doi-asserted-by":"publisher","first-page":"10039","DOI":"10.1200\/JCO.2023.41.16_suppl.10039","volume":"41","author":"\u00c1 Lassaletta","year":"2023","unstructured":"Lassaletta \u00c1, Moreno L, Ogawa C, Ruggiero A, Hoffman LM, Pitou C, et al. Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed\/refractory solid tumors (JPCS Part A). J Clin Oncol. 2023;41(16_suppl):10039.","journal-title":"J Clin Oncol"},{"issue":"32","key":"1208_CR38","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1200\/JCO.21.01152","volume":"39","author":"F Bautista","year":"2021","unstructured":"Bautista F, Paoletti X, Rubino J, Brard C, Rezai K, Nebchi S, et al. Phase I or II study of Ribociclib in combination with Topotecan-Temozolomide or Everolimus in children with advanced malignancies: Arms A and B of the AcS\u00e9-ESMART trial. J Clin Oncol. 2021;39(32):3546\u201360.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1208_CR39","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-20-4078","volume":"27","author":"MD DeWire","year":"2021","unstructured":"DeWire MD, Fuller C, Campagne O, Lin T, Pan H, Young Poussaint T, et al. A Phase I and surgical study of ribociclib and everolimus in children with recurrent or refractory malignant brain tumors: a Pediatric Brain Tumor Consortium study. Clin Cancer Res. 2021;27(9):2442\u201351.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1208_CR40","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s41375-022-01553-w","volume":"36","author":"R Chen","year":"2022","unstructured":"Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, et al. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia. 2022;36(6):1596\u2013608.","journal-title":"Leukemia"},{"key":"1208_CR41","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04983810 [Internet]. A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma."},{"key":"1208_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28879","author":"D Van Mater","year":"2021","unstructured":"Van Mater D, Gururangan S, Becher O, Campagne O, Leary S, Phillips JJ, et al. A Phase I trial of the CDK 4\/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: a Pediatric Brain Tumor Consortium study (PBTC\u2010042). Pediatr Blood Cancer. 2021. https:\/\/doi.org\/10.1002\/pbc.28879.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"1208_CR43","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-16-2898","volume":"23","author":"B Geoerger","year":"2017","unstructured":"Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, et al. A Phase I study of the CDK4\/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors. Clin Cancer Res. 2017;23(10):2433\u201341.","journal-title":"Clin Cancer Res"},{"key":"1208_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115629","volume":"226","author":"AD Pearson","year":"2025","unstructured":"Pearson AD, Chi S, Laetscht TW, Marshall L, Raetz E, George RE, et al. Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2025;226:115629.","journal-title":"Eur J Cancer"},{"issue":"22","key":"1208_CR45","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.1158\/1078-0432.CCR-13-1675","volume":"19","author":"J Rader","year":"2013","unstructured":"Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, et al. Dual CDK4\/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19(22):6173\u201382.","journal-title":"Clin Cancer Res"},{"key":"1208_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.957844","volume":"12","author":"T Higuchi","year":"2022","unstructured":"Higuchi T, Igarashi K, Yamamoto N, Hayashi K, Kimura H, Miwa S, et al. Review: precise sarcoma patient-derived orthotopic xenograft (PDOX) mouse models enable identification of novel effective combination therapies with the cyclin-dependent kinase inhibitor palbociclib: a strategy for clinical application. Front Oncol. 2022;12:957844.","journal-title":"Front Oncol"},{"issue":"30","key":"1208_CR47","doi-asserted-by":"publisher","first-page":"30178","DOI":"10.18632\/oncotarget.4903","volume":"6","author":"AL Kennedy","year":"2015","unstructured":"Kennedy AL, Vallurupalli M, Chen L, Crompton B, Cowley G, Vazquez F, et al. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1\/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015;6(30):30178\u201393.","journal-title":"Oncotarget"},{"issue":"8","key":"1208_CR48","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3324\/haematol.2021.279410","volume":"107","author":"KL Bride","year":"2021","unstructured":"Bride KL, Hu H, Tikhonova A, Fuller TJ, Vincent TL, Shraim R, et al. Rational drug combinations with CDK4\/6 inhibitors in acute lymphoblastic leukemia. Haematologica. 2021;107(8):1746\u201357.","journal-title":"Haematologica"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01208-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01208-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01208-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T18:01:50Z","timestamp":1774634510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01208-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01208-1","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was supported by grants from the Institut National du Cancer (INCa) within the AcS\u00e9 program, Association Imagine for Margo, Fondation ARC, F\u00e9d\u00e9ration Enfants et Sant\u00e9, Soci\u00e9t\u00e9 Fran\u00e7aise de lutte contre les Cancers et les leuc\u00e9mies de l\u2019Enfant et l\u2019adolescent (SFCE), Cancer Research UK, Dell, Cyclacel, and the Asociaci\u00f3n Pablo Ugarte in Spain. LVM is supported by the Oak Foundation via the Royal Marsden Cancer Charity, and BG by the \u2018Parrainage m\u00e9decin-chercheur\u2019 of Gustave Roussy. The trial was in part developed in the Joint ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research in Flims in 2014 (Francisco Bautista, BG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"ARS has had an advisory role for Eusapharma and SANOFI and an IDMC role for Miltenyi Biotec. LVM has had an advisory role for Alligator Biosciences, Bayer, DayOne Biopharmaceuticals, Illumina and Merck KGaA, and IDMC roles for Eisai and Merck. NA had an advisory role for MERCK and Norgine and receives grants (institution) from Bristol Myers Squibb and drugs for a trial from Bristol Myers Squibb, Pierre Fabre, MERCK, Pfizer and travel support from Roche, Novartis, Alexion; he has IDMC roles for ITM Radiopharma. SA has an advisory role for research funding support for FORE pharmaceutical, Lilly and Ipsen and is co inventory of a patent for temozolomide oral suspension. IA has had an advisory role for Alexion. SD has had an IDMC role for Orphelia Pharma. BG has had an advisory role for AstraZeneca, and IDMC roles for Roche and Novartis. EK, JR, SN, ET, CB, and GLT declare no conflict of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from parents, patients, or legal representatives.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data from this clinical trial are available from the authors and can be requested by completing the data request form for Gustave Roussy clinical trials at\n                      \n                      . The trial steering committee and the sponsor will review the requests on a case-by-case basis. A specific agreement between the sponsor and the researcher may be required for data transfer.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to collection and assembly of data, and to data analysis and interpretation. All authors critically reviewed the manuscript, provided final approval, and agreed to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}